España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Roche Holding
RHHBY
OTCQX
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$34.50
0.26
0.76%
At close: -
Get Report
Comment
Roche Holding (RHHBY) Forecast
News
Earnings
Roche Holding (RHHBY) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Roche Holding (OTC:RHHBY) Stock
Roche Holding Stock (OTC: RHHBY)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, December 19, 2024
Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits
Vandana Singh
Genentech's Prasinezumab Phase IIb Study Miss...
Benzinga Newsdesk
Wednesday, December 18, 2024
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
Vandana Singh
Friday, December 13, 2024
United Kingdom's National Health Service Drug Spending Priorities Questioned in New Analysis
Vandana Singh
Tuesday, December 10, 2024
Reported Earlier, Roche's Genentech Presents ...
Benzinga Newsdesk
Monday, December 09, 2024
Reported Sunday, Roche's Genentech Showcases ...
Benzinga Newsdesk
Thursday, December 05, 2024
FDA Accepts Genentech's sBLA For Columvi Comb...
Benzinga Newsdesk
Wednesday, November 27, 2024
Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?
Vandana Singh
Tuesday, November 26, 2024
Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details
Vandana Singh
Roche's Genentech Provides Update On SKYSCRAP...
Benzinga Newsdesk
Poseida Therapeutics To Be Acquired bB Roche ...
Benzinga Newsdesk
Monday, November 25, 2024
Roche Wins FDA Approval For The First Diagnos...
Benzinga Newsdesk
Monday, November 18, 2024
Roche Secures CE Mark For VENTANA FOLR1 RxDx ...
Benzinga Newsdesk
Friday, November 08, 2024
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
Vandana Singh
Wednesday, October 30, 2024
Reported Earlier, 'Novo Nordisk's Ozempic and...
Benzinga Newsdesk
Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
Avi Kapoor
Wednesday, October 23, 2024
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
Vandana Singh
Tuesday, October 15, 2024
Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer
Vandana Singh
Monday, October 14, 2024
Genentech's Evrysdi Two-Year Data Shows Promi...
Benzinga Newsdesk
Friday, October 11, 2024
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
Vandana Singh
Thursday, October 10, 2024
Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?
Vandana Singh
Tempest Therapeutics Enters Agreement With Ro...
Benzinga Newsdesk
Tuesday, October 08, 2024
Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer
Vandana Singh
Monday, October 07, 2024
Scholar Rock's Muscle Wasting Drug Excels In Pivotal Trial, Plans FDA Submission Next Year
Vandana Singh
Economist Justin Wolfers Points To Obesity Rate Decline As Ozempic And Wegovy Spur Historic Shift In Fight Against Obesity — Has US Reached A Turning Point?
Benzinga Neuro
Monday, September 30, 2024
Roche Fast-Tracks Obesity Drug Development, Eyes Over $3B Sales Potential
Vandana Singh
Thursday, September 26, 2024
Roche Group Member Genentech's Gazyva Shows R...
Benzinga Newsdesk
Thursday, September 19, 2024
Roche's Antiviral Drug Reduces Transmission Of Influenza Viruses, Late-Stage Study Shows
Vandana Singh
Roche's Genentech Phase III CENTERSTONE Study...
Benzinga Newsdesk
Monday, September 16, 2024
Back-To-Back FDA Approvals For Roche's Two Under-The-Skin Injections
Vandana Singh
Friday, September 13, 2024
Roche Group's Genentech Announces FDA Approve...
Benzinga Newsdesk
Reported Earlier, Roche's Genentech And Haloz...
Benzinga Newsdesk
Wednesday, September 11, 2024
Roche shares are trading lower following weig...
Benzinga Newsdesk
Roche Says In CT-996 Phase 1 Trial, 4-Week We...
Benzinga Newsdesk
Monday, September 09, 2024
Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease
Vandana Singh
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
Vandana Singh
Roche Expands AI-Driven Cancer Diagnostics Wi...
Benzinga Newsdesk
Thursday, September 05, 2024
Poseida Therapeutics To Present New Clinical ...
Benzinga Newsdesk
Thursday, August 29, 2024
Moderna And BioNTech Bet On Personalized Cancer Vaccines To Revive Fortunes After Dwindling COVID-19 Vaccine Sales
Vandana Singh
Monday, August 26, 2024
Diagnostic Giants Labcorp, Roche To Ramp Up Testing Capacity Amid Global Concerns Over New Mpox Strain
Vandana Singh
Friday, August 16, 2024
Roche Misses Out On Weight-Loss Blockbuster Drug, Now Playing Catch-Up In Booming Market
Vandana Singh
Thursday, August 15, 2024
Why Is Small-Cap Tempest Therapeutics Stock Trading Higher On Thursday?
Vandana Singh
Tuesday, August 13, 2024
Cancer-Focused Syros Pharmaceuticals Stops Mid-Stage Leukemia Combo Therapy Study, Cites Disappointing Unexpected Outcome
Vandana Singh
Thursday, August 08, 2024
Merck Stops Lung Cancer Study For Keytruda Combo Due To Ineffective Results, Side Effects
Vandana Singh
Wednesday, August 07, 2024
Roche Considers Selling Cancer Data Specialist Flatiron Health Business, Highlights Challenges With Start-Up Acquisitions
Vandana Singh
Monday, August 05, 2024
Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus
Vandana Singh
Thursday, August 01, 2024
Regeneron Tops on Q2 Earnings, Eylea HD, Dupixent Fuel Sales
Zacks
Thursday, July 25, 2024
Roche Holding H1 Adj. EPS CHF 10.23 Up From C...
Benzinga Newsdesk
Wednesday, July 24, 2024
Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On
Benzinga Neuro
Monday, July 22, 2024
Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier
Vandana Singh
Show More
